|
DE10214983A1
(de)
|
2002-04-04 |
2004-04-08 |
TransMIT Gesellschaft für Technologietransfer mbH |
Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
|
|
EP1519714B1
(en)
|
2002-06-28 |
2010-10-20 |
Protiva Biotherapeutics Inc. |
Method and apparatus for producing liposomes
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
ES2423060T3
(es)
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
|
CA2587411A1
(en)
*
|
2004-11-17 |
2006-05-26 |
Protiva Biotherapeutics, Inc. |
Sirna silencing of apolipoprotein b
|
|
US9393315B2
(en)
|
2011-06-08 |
2016-07-19 |
Nitto Denko Corporation |
Compounds for targeting drug delivery and enhancing siRNA activity
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
CN101346393B
(zh)
|
2005-11-02 |
2015-07-22 |
普洛体维生物治疗公司 |
修饰的siRNA分子及其应用
|
|
CN101484588B
(zh)
|
2006-05-11 |
2013-11-06 |
阿尔尼拉姆医药品有限公司 |
抑制pcsk9基因表达的组合物和方法
|
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
ES2535419T3
(es)
*
|
2007-12-27 |
2015-05-11 |
Protiva Biotherapeutics Inc. |
Silenciamiento de expresión de quinasa tipo polo usando ARN interferente
|
|
CA2713379A1
(en)
*
|
2008-01-31 |
2009-11-05 |
Alnylam Pharmaceuticals, Inc. |
Optimized methods for delivery of dsrna targeting the pcsk9 gene
|
|
KR101397407B1
(ko)
|
2008-03-05 |
2014-06-19 |
알닐람 파마슈티칼스 인코포레이티드 |
Eg5 및 VEGF 유전자의 발현을 억제하기 위한 조성물 및 방법
|
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
EP2299953B1
(en)
|
2008-07-14 |
2017-04-12 |
Polypid Ltd. |
Sustained-release drug carrier composition
|
|
AU2009296395A1
(en)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
|
|
CA2740000C
(en)
*
|
2008-10-09 |
2017-12-12 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
MX360460B
(es)
|
2008-10-20 |
2018-11-05 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion de transtiretina.
|
|
CN111808084A
(zh)
|
2008-11-10 |
2020-10-23 |
阿布特斯生物制药公司 |
用于递送治疗剂的新型脂质和组合物
|
|
CA2746514C
(en)
|
2008-12-10 |
2018-11-27 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
|
WO2010076248A1
(en)
*
|
2008-12-31 |
2010-07-08 |
Santaris Pharma A/S |
Use of lna apob antisense oligomers for the treatment of acute coronary syndromes
|
|
AU2010223967B2
(en)
*
|
2009-03-12 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
|
KR101184928B1
(ko)
*
|
2009-05-14 |
2012-09-20 |
한국과학기술연구원 |
작은 올리고뉴클레오티드의 중합 방법 및 상기 중합 방법에 의하여 제조된 고분자 올리고뉴클레오티드의 용도
|
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
|
JP5894913B2
(ja)
|
2009-06-15 |
2016-03-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Pcsk9遺伝子を標的とする、脂質で製剤化されたdsrna
|
|
DE102009031274A1
(de)
|
2009-06-30 |
2011-01-13 |
Justus-Liebig-Universität Giessen |
Liposomen zur pulmonalen Applikation
|
|
EP2449106B1
(en)
|
2009-07-01 |
2015-04-08 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
WO2011000107A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
|
IN2012DN00570A
(https=)
|
2009-07-14 |
2015-06-12 |
Polypid Ltd |
|
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
|
AP2015008874A0
(en)
|
2009-08-14 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
|
ES2579936T3
(es)
|
2009-08-20 |
2016-08-17 |
Sirna Therapeutics, Inc. |
Nuevos lípidos catiónicos con diversos grupos de cabeza para el suministro oligonucleotídico
|
|
CN107519133A
(zh)
|
2009-09-15 |
2017-12-29 |
阿尔尼拉姆医药品有限公司 |
脂质配制的组合物及抑制Eg5和VEGF基因的表达的方法
|
|
US9187746B2
(en)
|
2009-09-22 |
2015-11-17 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting siRNA agents
|
|
US9222086B2
(en)
|
2009-09-23 |
2015-12-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
US9101643B2
(en)
|
2009-11-03 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
|
|
CN107028886A
(zh)
|
2009-11-04 |
2017-08-11 |
不列颠哥伦比亚大学 |
含有核酸的脂质粒子及相关的方法
|
|
EP3318248B1
(en)
|
2009-12-01 |
2019-04-10 |
Translate Bio, Inc. |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
|
EP2525778B1
(en)
|
2010-01-19 |
2018-08-01 |
Polypid Ltd. |
Sustained-release nucleic acid matrix compositions
|
|
EP2555778A4
(en)
|
2010-04-06 |
2014-05-21 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING CD274 / PD-L1 GENE EXPRESSION
|
|
US20130037977A1
(en)
|
2010-04-08 |
2013-02-14 |
Paul A. Burke |
Preparation of Lipid Nanoparticles
|
|
US20130156845A1
(en)
*
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
|
WO2011141703A1
(en)
*
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
US20130123338A1
(en)
|
2010-05-12 |
2013-05-16 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
|
US8802863B2
(en)
|
2010-05-24 |
2014-08-12 |
Sirna Therapeutics, Inc. |
Amino alcohol cationic lipids for oligonucleotide delivery
|
|
CA3102008A1
(en)
|
2010-06-02 |
2011-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
ES2646669T3
(es)
|
2010-07-06 |
2017-12-14 |
Glaxosmithkline Biologicals Sa |
Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
|
|
EP2591114B1
(en)
|
2010-07-06 |
2016-06-08 |
GlaxoSmithKline Biologicals SA |
Immunisation of large mammals with low doses of rna
|
|
ES2557382T3
(es)
|
2010-07-06 |
2016-01-25 |
Glaxosmithkline Biologicals Sa |
Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
|
|
MX342608B
(es)
|
2010-07-06 |
2016-10-06 |
Novartis Ag * |
Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion.
|
|
NZ606591A
(en)
*
|
2010-07-06 |
2015-02-27 |
Novartis Ag |
Cationic oil-in-water emulsions
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US9029341B2
(en)
|
2010-08-17 |
2015-05-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
|
WO2012027467A1
(en)
|
2010-08-26 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
SI4043040T1
(sl)
|
2010-08-31 |
2023-04-28 |
Glaxosmithkline Biologicals Sa |
Mali liposomi za dostavo imunogen-kodirajoče RNA
|
|
JP2013541510A
(ja)
|
2010-08-31 |
2013-11-14 |
メルク・シャープ・エンド・ドーム・コーポレイション |
新規の単一の化学物質、およびオリゴヌクレオチドの送達方法
|
|
LT4226941T
(lt)
|
2010-08-31 |
2025-01-10 |
Glaxosmithkline Biologicals Sa |
Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
|
|
KR101223483B1
(ko)
*
|
2010-09-10 |
2013-01-17 |
한국과학기술연구원 |
전하결합 및 생분해성 공유결합으로 동시에 연결된 고분자―siRNA 나노입자 전달체
|
|
CA2809858C
(en)
|
2010-09-20 |
2019-11-12 |
Sirna Therapeutics, Inc. |
Novel low molecular weight cationic lipids for oligonucleotide delivery
|
|
CA2811430A1
(en)
|
2010-09-30 |
2012-04-05 |
Merck Sharp & Dohme Corp. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
EP2625189B1
(en)
|
2010-10-01 |
2018-06-27 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012051211A2
(en)
|
2010-10-11 |
2012-04-19 |
Novartis Ag |
Antigen delivery platforms
|
|
EP3485913A1
(en)
|
2010-10-21 |
2019-05-22 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
WO2012061259A2
(en)
|
2010-11-05 |
2012-05-10 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
|
EP2649182A4
(en)
|
2010-12-10 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for increasing erythropoietin (epo) production
|
|
EP2648763A4
(en)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
|
|
PH12013501969B1
(en)
|
2011-03-29 |
2018-08-31 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of tmprss6 gene
|
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
US20120301537A1
(en)
*
|
2011-05-23 |
2012-11-29 |
Delta-Fly Pharma, Inc. |
LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF
|
|
US8592572B2
(en)
*
|
2011-05-23 |
2013-11-26 |
Delta-Fly Pharma, Inc. |
Liposome containing shRNA molecule targeting a thymidylate synthase and use thereof
|
|
US9011903B2
(en)
|
2011-06-08 |
2015-04-21 |
Nitto Denko Corporation |
Cationic lipids for therapeutic agent delivery formulations
|
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
|
RU2013154295A
(ru)
*
|
2011-06-08 |
2015-07-20 |
Шир Хьюман Дженетик Терапис, Инк. |
КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК
|
|
EP3388068A1
(en)
|
2011-06-21 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
Composition and methods for inhibition of expression of protein c (proc) genes
|
|
MX390699B
(es)
|
2011-06-21 |
2025-03-21 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3).
|
|
US20140275211A1
(en)
|
2011-06-21 |
2014-09-18 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
|
EP2723758B1
(en)
|
2011-06-21 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
|
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
|
EP2729165B1
(en)
|
2011-07-06 |
2017-11-08 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
DE19216461T1
(de)
|
2011-10-03 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
|
|
JP2014530602A
(ja)
*
|
2011-10-05 |
2014-11-20 |
プロティバ バイオセラピューティクス インコーポレイテッド |
アルデヒドデヒドロゲナーゼをサイレンシングするための組成物および方法
|
|
WO2013059922A1
(en)
|
2011-10-25 |
2013-05-02 |
The University Of British Columbia |
Limit size lipid nanoparticles and related methods
|
|
US9320814B2
(en)
*
|
2011-11-01 |
2016-04-26 |
Board Of Regents Of The University Of Nebraska |
Polyplexes of hydrophobically-modified siRNA for delivery of siRNA
|
|
EP3730618A1
(en)
|
2011-11-18 |
2020-10-28 |
Alnylam Pharmaceuticals, Inc. |
Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
|
|
WO2013086354A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
WO2013086373A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
CA3018046A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
EP2817287B1
(en)
*
|
2012-02-24 |
2018-10-03 |
Arbutus Biopharma Corporation |
Trialkyl cationic lipids and methods of use thereof
|
|
BR112014024131A2
(pt)
|
2012-03-29 |
2017-07-25 |
Shire Human Genetic Therapies |
lipídios catiônicos ionizáveis
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
CN104411338A
(zh)
*
|
2012-04-02 |
2015-03-11 |
现代治疗公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
AU2013249548A1
(en)
|
2012-04-19 |
2014-11-06 |
Sirna Therapeutics, Inc. |
Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
WO2013185067A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
EP2858679B2
(en)
|
2012-06-08 |
2024-06-05 |
Translate Bio, Inc. |
Pulmonary delivery of mrna to non-lung target cells
|
|
WO2014008334A1
(en)
|
2012-07-06 |
2014-01-09 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
|
CN102719437A
(zh)
*
|
2012-07-11 |
2012-10-10 |
潍坊医学院 |
利用慢病毒载体介导PLK1 RNAi在治疗食管鳞癌转移中的应用
|
|
WO2014028429A2
(en)
|
2012-08-14 |
2014-02-20 |
Moderna Therapeutics, Inc. |
Enzymes and polymerases for the synthesis of rna
|
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
|
IL292159B1
(en)
|
2012-12-05 |
2026-04-01 |
Alnylam Pharmaceuticals Inc |
PCSK9 iRNA compositions and methods of using them
|
|
EP3031921B1
(en)
|
2012-12-12 |
2025-03-12 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
JP6586075B2
(ja)
|
2013-03-14 |
2019-10-02 |
トランスレイト バイオ, インコーポレイテッド |
メッセンジャーrnaの精製方法
|
|
BR112015022855A2
(pt)
|
2013-03-14 |
2017-11-07 |
Shire Human Genetic Therapies |
composições e método para produção de um anticorpo in vitro
|
|
IL288931B2
(en)
|
2013-03-14 |
2025-05-01 |
Alnylam Pharmaceuticals Inc |
Compositions comprising a complementary portion of C5 IRNA and methods of using them
|
|
RS57739B1
(sr)
|
2013-03-14 |
2018-12-31 |
Translate Bio Inc |
Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima
|
|
US20160032316A1
(en)
|
2013-03-14 |
2016-02-04 |
The Trustees Of The University Of Pennsylvania |
Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
|
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
WO2014152027A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Manufacturing methods for production of rna transcripts
|
|
EP2971165A4
(en)
|
2013-03-15 |
2016-11-23 |
Moderna Therapeutics Inc |
DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
|
|
US10590161B2
(en)
|
2013-03-15 |
2020-03-17 |
Modernatx, Inc. |
Ion exchange purification of mRNA
|
|
EP3388834B1
(en)
|
2013-03-15 |
2020-04-15 |
Translate Bio, Inc. |
Synergistic enhancement of the delivery of nucleic acids via blended formulations
|
|
CN105143456A
(zh)
|
2013-03-15 |
2015-12-09 |
不列颠哥伦比亚大学 |
用于转染的脂质纳米粒子和相关方法
|
|
WO2014140856A2
(en)
|
2013-03-15 |
2014-09-18 |
Graham Lord |
Mir-142 and antagonists thereof for treating disease
|
|
WO2014152031A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Ribonucleic acid purification
|
|
KR102234623B1
(ko)
|
2013-05-22 |
2021-04-02 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 조성물 및 이의 사용 방법
|
|
EA038792B1
(ru)
|
2013-05-22 |
2021-10-20 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ НА ОСНОВЕ RNAi Serpina1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
MX374532B
(es)
|
2013-06-17 |
2025-03-06 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
|
|
CN105683379A
(zh)
|
2013-06-17 |
2016-06-15 |
布罗德研究所有限公司 |
用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化
|
|
RU2716420C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
|
|
CA2917348A1
(en)
|
2013-07-11 |
2015-01-15 |
Moderna Therapeutics, Inc. |
Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
|
|
JP6620093B2
(ja)
|
2013-07-23 |
2019-12-11 |
アービュートゥス バイオファーマ コーポレイションArbutus Biopharma Corporation |
メッセンジャーrnaを送達するための組成物及び方法
|
|
EP3041934A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
CA2925107A1
(en)
|
2013-10-02 |
2015-04-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
EP3052511A4
(en)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
LT3052628T
(lt)
|
2013-10-04 |
2020-09-10 |
Alnylam Pharmaceuticals, Inc. |
Kompozicijos ir būdai alas1 geno raiškai nuslopinti
|
|
ES3032935T3
(en)
|
2013-10-22 |
2025-07-29 |
Translate Bio Inc |
Lipid formulations for delivery of messenger rna
|
|
CN106413811A
(zh)
|
2013-10-22 |
2017-02-15 |
夏尔人类遗传性治疗公司 |
精氨基琥珀酸合成酶缺乏症的mrna疗法
|
|
AU2014340149B2
(en)
|
2013-10-22 |
2020-12-24 |
Shire Human Genetic Therapies, Inc. |
CNS delivery of mRNA and uses thereof
|
|
JP6506749B2
(ja)
|
2013-10-22 |
2019-04-24 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
フェニルケトン尿症のためのmRNA療法
|
|
SI3071696T1
(sl)
|
2013-11-22 |
2019-11-29 |
Mina Therapeutics Ltd |
C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe
|
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
SG10201804975PA
(en)
|
2013-12-12 |
2018-07-30 |
Broad Inst Inc |
Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
|
|
JP7103750B2
(ja)
|
2013-12-12 |
2022-07-20 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ゲノム編集のためのCRISPR-Cas系及び組成物の送達、使用及び治療適用
|
|
EP3470089A1
(en)
|
2013-12-12 |
2019-04-17 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
|
JP6712948B2
(ja)
|
2013-12-12 |
2020-06-24 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
組成物、及びヌクレオチドリピート障害におけるcrispr−cas系の使用方法
|
|
SG10201804960RA
(en)
|
2013-12-12 |
2018-07-30 |
Alnylam Pharmaceuticals Inc |
Complement component irna compositions and methods of use thereof
|
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
|
|
CN113057959B
(zh)
|
2014-02-11 |
2024-07-16 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
|
US10821175B2
(en)
|
2014-02-25 |
2020-11-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
PL4023249T3
(pl)
*
|
2014-04-23 |
2025-03-10 |
Modernatx, Inc. |
Szczepionki z kwasem nukleinowym
|
|
US9850269B2
(en)
|
2014-04-25 |
2017-12-26 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
|
AU2015264038B2
(en)
|
2014-05-22 |
2021-02-11 |
Alnylam Pharmaceuticals, Inc. |
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
|
|
JP6557722B2
(ja)
|
2014-05-30 |
2019-08-07 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
核酸の送達のための生分解性脂質
|
|
CN106536056B
(zh)
|
2014-06-13 |
2021-07-16 |
儿童医学中心公司 |
分离线粒体的产品和方法
|
|
WO2015196128A2
(en)
|
2014-06-19 |
2015-12-23 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
KR102559979B1
(ko)
|
2014-06-24 |
2023-07-25 |
샤이어 휴먼 지네틱 테라피즈 인크. |
핵산의 전달용 입체화학적으로 풍부한 조성물
|
|
HUE060907T2
(hu)
|
2014-06-25 |
2023-04-28 |
Acuitas Therapeutics Inc |
Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
|
|
BR112016030852A2
(pt)
|
2014-07-02 |
2018-01-16 |
Shire Human Genetic Therapies |
encapsulação de rna mensageiro
|
|
US10407683B2
(en)
|
2014-07-16 |
2019-09-10 |
Modernatx, Inc. |
Circular polynucleotides
|
|
CN106794141B
(zh)
*
|
2014-07-16 |
2021-05-28 |
诺华股份有限公司 |
将核酸包封在脂质纳米粒主体中的方法
|
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EP3171895A1
(en)
|
2014-07-23 |
2017-05-31 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
WO2016028682A1
(en)
|
2014-08-17 |
2016-02-25 |
The Broad Institute Inc. |
Genome editing using cas9 nickases
|
|
US9765333B2
(en)
|
2014-08-21 |
2017-09-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing marburg virus gene expression
|
|
CN113599539A
(zh)
|
2014-08-29 |
2021-11-05 |
阿尔尼拉姆医药品有限公司 |
治疗甲状腺素运载蛋白(ttr)介导的淀粉样变性的方法
|
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
EP3201338B1
(en)
|
2014-10-02 |
2021-11-03 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing hepatitis b virus gene expression
|
|
TW202503057A
(zh)
|
2014-10-10 |
2025-01-16 |
美商艾爾妮蘭製藥公司 |
用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
|
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
EP3212794B1
(en)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
|
KR102545316B1
(ko)
|
2014-11-10 |
2023-06-22 |
알닐람 파마슈티칼스 인코포레이티드 |
B형 간염 바이러스(hbv) irna 조성물 및 그의 이용 방법
|
|
JP2017535552A
(ja)
|
2014-11-17 |
2017-11-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法
|
|
JP6767976B2
(ja)
|
2014-12-05 |
2020-10-14 |
トランスレイト バイオ, インコーポレイテッド |
関節疾患の治療のためのメッセンジャーrna治療法
|
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
JP2018504380A
(ja)
|
2014-12-18 |
2018-02-15 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Reversir(商標)化合物
|
|
EP3234192B1
(en)
|
2014-12-19 |
2021-07-14 |
The Broad Institute, Inc. |
Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
|
JP2018509387A
(ja)
|
2015-01-21 |
2018-04-05 |
フェーズアールエックス インコーポレイテッド |
細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム
|
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
WO2016149508A1
(en)
|
2015-03-19 |
2016-09-22 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for pompe disease
|
|
US10745702B2
(en)
|
2015-04-08 |
2020-08-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
|
EP4353257A3
(en)
|
2015-04-13 |
2024-08-07 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
|
CN104997801A
(zh)
*
|
2015-05-28 |
2015-10-28 |
厦门成坤生物技术有限公司 |
包含季铵盐类化合物和siRNA的组合物及其制备方法
|
|
WO2016197132A1
(en)
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics Inc. |
Treating hepatitis b virus infection using crispr
|
|
WO2016201301A1
(en)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
AU2016279077A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
EP3310918B1
(en)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
|
WO2016205745A2
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Cell sorting
|
|
TWI906646B
(zh)
|
2015-06-18 |
2025-12-01 |
美商博得學院股份有限公司 |
降低脫靶效應的crispr酶突變
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
PT3313829T
(pt)
|
2015-06-29 |
2024-07-08 |
Acuitas Therapeutics Inc |
Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
|
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
|
JP2018528257A
(ja)
*
|
2015-07-10 |
2018-09-27 |
ペプティノボ・バイオファーマ・リミテッド・ライアビリティ・カンパニーPeptinovo Biopharma, LLC |
疎水性薬剤の効能を改善するための配合物
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
MA42502A
(fr)
|
2015-07-21 |
2018-05-30 |
Modernatx Inc |
Vaccins contre une maladie infectieuse
|
|
WO2017019891A2
(en)
|
2015-07-29 |
2017-02-02 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing hepatitis b virus gene expression
|
|
MA42543A
(fr)
|
2015-07-30 |
2018-06-06 |
Modernatx Inc |
Arn épitope peptidiques concatémériques
|
|
PT3329002T
(pt)
|
2015-07-31 |
2021-01-12 |
Alnylam Pharmaceuticals Inc |
Composições de iarn de transtirretina (ttr) e métodos de seu uso para tratamento ou prevenção de doenças associadas à ttr
|
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
WO2017031370A1
(en)
|
2015-08-18 |
2017-02-23 |
The Broad Institute, Inc. |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
|
WO2017035278A1
(en)
|
2015-08-24 |
2017-03-02 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
|
CA2996873A1
(en)
|
2015-09-02 |
2017-03-09 |
Alnylam Pharmaceuticals, Inc. |
Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof
|
|
WO2017048620A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
|
WO2017049286A1
(en)
|
2015-09-17 |
2017-03-23 |
Moderna Therapeutics, Inc. |
Polynucleotides containing a morpholino linker
|
|
EP3350333B2
(en)
|
2015-09-17 |
2025-08-06 |
ModernaTX, Inc. |
Polynucleotides containing a stabilizing tail region
|
|
JP6948313B6
(ja)
|
2015-09-17 |
2022-01-14 |
モデルナティエックス インコーポレイテッド |
治療剤の細胞内送達のための化合物および組成物
|
|
EP3359670B2
(en)
|
2015-10-05 |
2024-02-14 |
ModernaTX, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
JP6997704B2
(ja)
|
2015-10-14 |
2022-02-04 |
トランスレイト バイオ, インコーポレイテッド |
生産性向上のためのrna関連酵素の修飾
|
|
EP4647126A3
(en)
|
2015-10-16 |
2026-02-11 |
Ipsen Biopharm Ltd. |
Stabilizing camptothecin pharmaceutical compositions
|
|
CN116814590A
(zh)
|
2015-10-22 |
2023-09-29 |
布罗德研究所有限公司 |
Vi-b型crispr酶和系统
|
|
AU2016342376A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
|
WO2017070601A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
AU2016341309A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Cancer vaccines
|
|
AU2016342045A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
|
EP3368687B1
(en)
|
2015-10-27 |
2021-09-29 |
The Broad Institute, Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
HRP20230209T1
(hr)
|
2015-10-28 |
2023-04-14 |
Acuitas Therapeutics Inc. |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
US11903974B2
(en)
|
2015-11-30 |
2024-02-20 |
Flagship Pioneering Innovations V, Inc. |
Methods and compositions relating to chondrisomes from cultured cells
|
|
PL3386484T3
(pl)
|
2015-12-10 |
2022-07-25 |
Modernatx, Inc. |
Kompozycje i sposoby dostarczania środków terapeutycznych
|
|
US12110490B2
(en)
|
2015-12-18 |
2024-10-08 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
LT3394030T
(lt)
|
2015-12-22 |
2022-04-11 |
Modernatx, Inc. |
Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
|
|
PL3394093T3
(pl)
|
2015-12-23 |
2022-05-16 |
Modernatx, Inc. |
Metody stosowania polinukleotydów kodujących ligand ox40
|
|
MA43587A
(fr)
|
2016-01-10 |
2018-11-14 |
Modernatx Inc |
Arnm thérapeutiques codant pour des anticorps anti-ctla-4
|
|
WO2017124037A1
(en)
|
2016-01-15 |
2017-07-20 |
The Children's Medical Center Corporation |
Therapeutic use of mitochondria and combined mitochondrial agents
|
|
EP3825400B1
(en)
|
2016-04-08 |
2024-12-25 |
Translate Bio, Inc. |
Multimeric coding nucleic acid and uses thereof
|
|
AU2017257274B2
(en)
|
2016-04-19 |
2023-07-13 |
Massachusetts Institute Of Technology |
Novel CRISPR enzymes and systems
|
|
KR20260004568A
(ko)
|
2016-04-19 |
2026-01-08 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규한 crispr 효소 및 시스템
|
|
EP3445853A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
WO2017184689A1
(en)
|
2016-04-19 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
High density lipoprotein binding protein (hdlbp/vigilin) irna compositions and methods of use thereof
|
|
JP7194594B2
(ja)
|
2016-05-18 |
2022-12-22 |
モデルナティエックス インコーポレイテッド |
免疫調節ポリペプチドをコードするmRNAの組み合わせ及びその使用
|
|
IL263079B2
(en)
|
2016-05-18 |
2024-05-01 |
Modernatx Inc |
Polynucleotides encoding relaxin
|
|
WO2017201342A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding jagged1 for the treatment of alagille syndrome
|
|
SI3458083T1
(sl)
|
2016-05-18 |
2023-03-31 |
Modernatx, Inc. |
Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba
|
|
EP3469083A1
(en)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
|
EP3469074B1
(en)
|
2016-06-13 |
2020-12-09 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
|
|
WO2017218704A1
(en)
*
|
2016-06-14 |
2017-12-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CN109642231A
(zh)
|
2016-06-17 |
2019-04-16 |
博德研究所 |
Vi型crispr直向同源物和系统
|
|
WO2017223176A1
(en)
|
2016-06-24 |
2017-12-28 |
Modernatx, Inc. |
Methods and apparatus for filtration
|
|
US12595478B2
(en)
|
2016-06-29 |
2026-04-07 |
The Broad Institute, Inc. |
Crispr-Cas systems having destabilization domain
|
|
CN109563511A
(zh)
|
2016-06-30 |
2019-04-02 |
阿布特斯生物制药公司 |
用于递送信使rna的组合物和方法
|
|
MX2019000205A
(es)
|
2016-07-07 |
2019-09-23 |
Rubius Therapeutics Inc |
Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
|
|
EP4485466A3
(en)
|
2016-08-17 |
2025-04-02 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
WO2018035387A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
CN109715205A
(zh)
|
2016-08-19 |
2019-05-03 |
库瑞瓦格股份公司 |
用于癌症治疗的rna
|
|
EP3500294A4
(en)
|
2016-08-22 |
2020-07-29 |
Arbutus Biopharma Corporation |
ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
US12499971B2
(en)
|
2016-09-28 |
2025-12-16 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
WO2018119514A1
(en)
*
|
2016-12-28 |
2018-07-05 |
Precision Nanosystems Inc. |
Compositions for transfecting resistant cell types
|
|
WO2018064755A1
(en)
|
2016-10-03 |
2018-04-12 |
Precision Nanosystems Inc. |
Compositions for transfecting resistant cell types
|
|
US12447213B2
(en)
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
EP3528821A4
(en)
|
2016-10-21 |
2020-07-01 |
ModernaTX, Inc. |
HUMAN CYTOMEGALOVIRUS VACCINE
|
|
EP3532103B1
(en)
|
2016-10-26 |
2025-12-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
MA46766A
(fr)
|
2016-11-11 |
2019-09-18 |
Modernatx Inc |
Vaccin antigrippal
|
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
|
WO2018107088A2
(en)
|
2016-12-08 |
2018-06-14 |
Modernatx, Inc. |
Respiratory virus nucleic acid vaccines
|
|
EP3551230A1
(en)
|
2016-12-08 |
2019-10-16 |
CureVac AG |
Rna for treatment or prophylaxis of a liver disease
|
|
WO2018112320A1
(en)
|
2016-12-16 |
2018-06-21 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
|
US11464847B2
(en)
|
2016-12-23 |
2022-10-11 |
Curevac Ag |
Lassa virus vaccine
|
|
EA201991747A1
(ru)
|
2017-02-27 |
2020-06-04 |
Транслейт Био, Инк. |
НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
WO2018170322A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
CA3055653A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
JP2020511141A
(ja)
|
2017-03-15 |
2020-04-16 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
新規Cas13bオルソログCRISPR酵素及び系
|
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
RESPIRATORY SYNCYTIAL VIRUS Vaccine
|
|
EP4186888B1
(en)
|
2017-03-15 |
2025-11-26 |
ModernaTX, Inc. |
Compound and compositions for intracellular delivery of therapeutic agents
|
|
WO2018170256A1
(en)
*
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
EP3595676A4
(en)
|
2017-03-17 |
2021-05-05 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZOONOSES
|
|
JP2020514370A
(ja)
|
2017-03-17 |
2020-05-21 |
キュアバック アーゲー |
組合せ抗癌療法のためのrnaワクチン及び免疫チェックポイント阻害剤
|
|
EP3596112A2
(en)
|
2017-03-17 |
2020-01-22 |
Newcastle University |
Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
|
|
SG11201906297QA
(en)
|
2017-03-24 |
2019-10-30 |
Curevac Ag |
Nucleic acids encoding crispr-associated proteins and uses thereof
|
|
US11905525B2
(en)
|
2017-04-05 |
2024-02-20 |
Modernatx, Inc. |
Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
AU2018251801B2
(en)
|
2017-04-12 |
2024-11-07 |
Massachusetts Institute Of Technology |
Novel type VI CRISPR orthologs and systems
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
WO2018191750A2
(en)
|
2017-04-14 |
2018-10-18 |
The Broad Institute Inc. |
Novel delivery of large payloads
|
|
CA3059446A1
(en)
|
2017-04-18 |
2018-10-25 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
|
|
CN110799492B
(zh)
|
2017-04-28 |
2023-06-27 |
爱康泰生治疗公司 |
用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
|
|
US11591601B2
(en)
|
2017-05-05 |
2023-02-28 |
The Broad Institute, Inc. |
Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
|
|
CA3062426A1
(en)
|
2017-05-08 |
2018-11-15 |
Flagship Pioneering Innovations V, Inc. |
Compositions for facilitating membrane fusion and uses thereof
|
|
MX2019013752A
(es)
|
2017-05-16 |
2020-07-20 |
Translate Bio Inc |
Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
|
|
WO2018213726A1
(en)
|
2017-05-18 |
2018-11-22 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
ES3039647T3
(en)
|
2017-05-31 |
2025-10-23 |
Arcturus Therapeutics Inc |
Synthesis and structure of high potency rna therapeutics
|
|
EP3630200A4
(en)
|
2017-05-31 |
2021-02-24 |
Arcturus Therapeutics, Inc. |
THERAPEUTICS FOR PHENYLKETONURIA
|
|
BR112019025224A2
(pt)
|
2017-05-31 |
2020-12-08 |
Ultragenyx Pharmaceutical Inc. |
Terapêutica para doença de armazenamento de glicogênio tipo iii
|
|
IL271275B1
(en)
|
2017-06-13 |
2026-04-01 |
Flagship Pioneering Innovations V Inc |
Preparations containing croons and their uses
|
|
WO2018232120A1
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
MA49421A
(fr)
|
2017-06-15 |
2020-04-22 |
Modernatx Inc |
Formulations d'arn
|
|
SG11201911430PA
(en)
|
2017-07-04 |
2020-01-30 |
Curevac Ag |
Novel nucleic acid molecules
|
|
EP3652317A1
(en)
|
2017-07-13 |
2020-05-20 |
Alnylam Pharmaceuticals, Inc. |
Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
|
|
CA3073020A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
EP4501322A3
(en)
|
2017-08-17 |
2025-04-16 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
|
WO2019040516A1
(en)
|
2017-08-22 |
2019-02-28 |
Rubius Therapeutics, Inc. |
METHODS AND COMPOSITIONS OF LIPID NANOPARTICLES FOR THE PRODUCTION OF MODIFIED ERYTHROID CELLS
|
|
EP3675817A1
(en)
|
2017-08-31 |
2020-07-08 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
WO2019048632A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
|
|
US20200208152A1
(en)
|
2017-09-08 |
2020-07-02 |
Mina Therapeutics Limited |
Stabilized sarna compositions and methods of use
|
|
WO2019055807A1
(en)
|
2017-09-14 |
2019-03-21 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZIKA VIRUS
|
|
BR112020005230A2
(pt)
|
2017-09-19 |
2020-09-24 |
Alnylam Pharmaceuticals, Inc. |
composições e métodos para o tratamento da amiloidose mediada por transtiretina (ttr)
|
|
AU2018338318B2
(en)
|
2017-09-21 |
2022-12-22 |
Massachusetts Institute Of Technology |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
WO2019071054A1
(en)
|
2017-10-04 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS
|
|
US20220233568A1
(en)
|
2017-10-19 |
2022-07-28 |
Curevac Ag |
Novel artificial nucleic acid molecules
|
|
WO2019135816A2
(en)
|
2017-10-23 |
2019-07-11 |
The Broad Institute, Inc. |
Novel nucleic acid modifiers
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
WO2019089803A1
(en)
|
2017-10-31 |
2019-05-09 |
The Broad Institute, Inc. |
Methods and compositions for studying cell evolution
|
|
CN111511924A
(zh)
|
2017-11-08 |
2020-08-07 |
库瑞瓦格股份公司 |
Rna序列调整
|
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
|
|
US20200385719A1
(en)
|
2017-11-16 |
2020-12-10 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
|
EP3723796A1
(en)
|
2017-12-13 |
2020-10-21 |
CureVac AG |
Flavivirus vaccine
|
|
WO2019118806A1
(en)
|
2017-12-14 |
2019-06-20 |
Solid Biosciences Inc. |
Non-viral production and delivery of genes
|
|
EP3728593A1
(en)
|
2017-12-18 |
2020-10-28 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
|
|
US11167043B2
(en)
|
2017-12-20 |
2021-11-09 |
Translate Bio, Inc. |
Composition and methods for treatment of ornithine transcarbamylase deficiency
|
|
WO2019126709A1
(en)
|
2017-12-22 |
2019-06-27 |
The Broad Institute, Inc. |
Cas12b systems, methods, and compositions for targeted dna base editing
|
|
TWI894123B
(zh)
*
|
2017-12-27 |
2025-08-21 |
日商武田藥品工業有限公司 |
含核酸之脂質奈米粒子及其用途
|
|
US12539308B2
(en)
|
2018-01-08 |
2026-02-03 |
The Trustees Of The University Of Pennsylvania |
Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
|
|
WO2019140116A2
(en)
|
2018-01-10 |
2019-07-18 |
Rubius Therapeutics, Inc. |
Amplifiable rnas for therapeutic cell systems
|
|
EP3746090A4
(en)
|
2018-01-29 |
2021-11-17 |
ModernaTX, Inc. |
RSV RNA Vaccines
|
|
US20190269728A1
(en)
|
2018-03-02 |
2019-09-05 |
Sixfold Bioscience Ltd. |
Compositions for delivery of cargo to cells
|
|
WO2019193183A2
(en)
|
2018-04-05 |
2019-10-10 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
|
SG11202009877XA
(en)
|
2018-04-12 |
2020-11-27 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods of use thereof
|
|
EP3775211B1
(en)
|
2018-04-12 |
2023-04-05 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
AU2019254591B2
(en)
|
2018-04-17 |
2025-12-11 |
CureVac SE |
Novel RSV RNA molecules and compositions for vaccination
|
|
US12391942B2
(en)
|
2018-05-11 |
2025-08-19 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
TWI851574B
(zh)
|
2018-05-14 |
2024-08-11 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
|
KR102591743B1
(ko)
|
2018-06-08 |
2023-10-19 |
후지필름 가부시키가이샤 |
화합물 또는 그 염 및 지질 입자
|
|
MY208145A
(en)
|
2018-06-18 |
2025-04-18 |
Res Inst Nationwide Childrens Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
|
US12357580B2
(en)
|
2018-06-19 |
2025-07-15 |
The Board Of Regents Of The University Of Texas System |
Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
|
|
WO2020051223A1
(en)
|
2018-09-04 |
2020-03-12 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for organ specific delivery of nucleic acids
|
|
EP3813874A1
(en)
|
2018-06-27 |
2021-05-05 |
CureVac AG |
Novel lassa virus rna molecules and compositions for vaccination
|
|
JP2021532815A
(ja)
|
2018-08-07 |
2021-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
新規Cas12b酵素およびシステム
|
|
TW202020157A
(zh)
|
2018-08-16 |
2020-06-01 |
美商艾爾妮蘭製藥公司 |
用於抑制lect2基因表現之組合物及方法
|
|
US12421507B2
(en)
|
2018-08-20 |
2025-09-23 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of CRISPR-CAS9
|
|
KR102950141B1
(ko)
|
2018-08-24 |
2026-04-07 |
트랜슬레이트 바이오 인코포레이티드 |
전령 rna의 정제 방법
|
|
EP3846857A4
(en)
|
2018-09-04 |
2022-10-12 |
The Board Of Regents Of The University Of Texas System |
COMPOSITIONS AND METHODS FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS
|
|
US20210332367A1
(en)
|
2018-09-18 |
2021-10-28 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
CA3113025A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
|
WO2020061295A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
IL281615B2
(en)
|
2018-09-21 |
2026-01-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
EP3856757A4
(en)
|
2018-09-28 |
2022-06-29 |
Nutcracker Therapeutics, Inc. |
Tertiary amino lipidated cationic peptides for nucleic acid delivery
|
|
CA3114435A1
(en)
*
|
2018-10-01 |
2020-04-09 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
HRP20240586T1
(hr)
|
2018-10-09 |
2024-07-19 |
The University Of British Columbia |
Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima
|
|
CA3116576A1
(en)
|
2018-10-18 |
2020-04-23 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
|
EP3876999A4
(en)
|
2018-11-09 |
2022-08-31 |
Arbutus Biopharma Corporation |
NEGATIVELY CHARGED PEG-LIPID CONJUGATES
|
|
KR20210105889A
(ko)
|
2018-11-09 |
2021-08-27 |
아뷰터스 바이오파마 코포레이션 |
지질 나노입자 제제
|
|
AU2019376006A1
(en)
|
2018-11-09 |
2021-06-03 |
Arbutus Biopharma Corporation |
Cationic lipids containing silicon
|
|
WO2020106946A1
(en)
|
2018-11-21 |
2020-05-28 |
Translate Bio, Inc. |
TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
|
|
WO2020117706A1
(en)
|
2018-12-03 |
2020-06-11 |
Triplet Therapeutics, Inc. |
Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
|
|
AU2019394996B2
(en)
|
2018-12-06 |
2025-11-06 |
Arcturus Therapeutics, Inc. |
Compositions and methods for treating ornithine transcarbamylase deficiency
|
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
|
AU2019406186A1
(en)
|
2018-12-20 |
2021-07-15 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of KCNT1 related disorders
|
|
WO2020128816A2
(en)
|
2018-12-20 |
2020-06-25 |
Pfizer Inc. |
Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
|
|
BR112021009422A2
(pt)
|
2018-12-21 |
2021-10-26 |
Curevac Ag |
Rna para vacinas contra malária
|
|
US12042527B2
(en)
|
2019-01-08 |
2024-07-23 |
Modernatx, Inc. |
Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
PT3908568T
(pt)
|
2019-01-11 |
2024-09-30 |
Acuitas Therapeutics Inc |
Lípidos para a administração de agentes ativos por nanopartículas lipídicas
|
|
US20220133908A1
(en)
|
2019-02-08 |
2022-05-05 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
US12070495B2
(en)
|
2019-03-15 |
2024-08-27 |
Modernatx, Inc. |
HIV RNA vaccines
|
|
US12534714B2
(en)
|
2019-03-18 |
2026-01-27 |
The Broad Institute, Inc. |
Type VII CRISPR proteins and systems
|
|
EP3953473A1
(en)
|
2019-04-12 |
2022-02-16 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
WO2020236972A2
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
|
EP3980533A1
(en)
|
2019-06-07 |
2022-04-13 |
Scribe Therapeutics Inc. |
Engineered casx systems
|
|
WO2020246581A1
(ja)
|
2019-06-07 |
2020-12-10 |
富士フイルム株式会社 |
脂質組成物
|
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
|
JP7759311B2
(ja)
|
2019-07-19 |
2025-10-23 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
リコンビナーゼ組成物及び使用方法
|
|
CA3145913A1
(en)
|
2019-07-29 |
2021-02-04 |
James Everett Dahlman |
Nanomaterials containing constrained lipids and uses thereof
|
|
JP7692829B2
(ja)
|
2019-07-30 |
2025-06-16 |
塩野義製薬株式会社 |
Murf1を標的とする核酸医薬
|
|
EP4007811A2
(en)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof
|
|
EP4007812A1
(en)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
|
|
EP4013870A1
(en)
|
2019-08-13 |
2022-06-22 |
Alnylam Pharmaceuticals, Inc. |
Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
|
|
CN114901253A
(zh)
|
2019-08-14 |
2022-08-12 |
爱康泰生治疗公司 |
用于递送核酸的改进的脂质纳米颗粒
|
|
CN114502204A
(zh)
|
2019-08-14 |
2022-05-13 |
库尔维科公司 |
具有降低的免疫刺激性质的rna组合和组合物
|
|
WO2021034639A1
(en)
|
2019-08-16 |
2021-02-25 |
Regeneron Pharmaceuticals, Inc. |
High concentration anti-c5 formulations
|
|
WO2021053405A2
(en)
|
2019-08-30 |
2021-03-25 |
Sixfold Bioscience Ltd. |
Compositions for transfer of cargo to cells
|
|
BR112022003860A2
(pt)
|
2019-09-03 |
2022-08-16 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para inibir a expressão do gene lect2
|
|
WO2021046265A1
(en)
|
2019-09-06 |
2021-03-11 |
Generation Bio Co. |
Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof
|
|
CA3155015A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
AU2020350759A1
(en)
|
2019-09-19 |
2022-03-31 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
EP4031662A1
(en)
|
2019-09-20 |
2022-07-27 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
|
US12503699B2
(en)
|
2019-10-04 |
2025-12-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing UGT1a1 gene expression
|
|
EP4045652A1
(en)
|
2019-10-18 |
2022-08-24 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
|
WO2021081026A1
(en)
|
2019-10-22 |
2021-04-29 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
|
CA3153195A1
(en)
|
2019-10-25 |
2021-04-29 |
John Davis |
Dosing regimens for treating or preventing c5-associated diseases
|
|
EP4051795A1
(en)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
|
US20230040920A1
(en)
|
2019-11-01 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
BR112022009216A2
(pt)
|
2019-11-13 |
2022-08-02 |
Alnylam Pharmaceuticals Inc |
Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt)
|
|
EP4059505B1
(en)
|
2019-11-15 |
2024-02-21 |
FUJIFILM Corporation |
Lipid composition
|
|
CR20220220A
(es)
|
2019-11-18 |
2022-09-20 |
Janssen Biotech Inc |
Vacunas basadas en calr y jak2 mutantes y sus usos
|
|
JP2023502576A
(ja)
|
2019-11-22 |
2023-01-25 |
ジェネレーション バイオ カンパニー |
イオン化可能な脂質およびそれらのナノ粒子組成物
|
|
US12565653B2
(en)
|
2019-11-22 |
2026-03-03 |
Alnylam Pharmaceuticals, Inc. |
ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof
|
|
KR20220115995A
(ko)
|
2019-12-13 |
2022-08-19 |
알닐람 파마슈티칼스 인코포레이티드 |
인간 염색체 9 개방 판독 프레임 72 (C9orf72) iRNA 제제 조성물 및 이의 사용 방법
|
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
CN114901360A
(zh)
|
2019-12-20 |
2022-08-12 |
库瑞瓦格股份公司 |
用于递送核酸的新型脂质纳米颗粒
|
|
IL294318A
(en)
|
2020-01-09 |
2022-08-01 |
Guide Therapeutics Llc |
Nanomaterials
|
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
|
KR20220144416A
(ko)
|
2020-02-04 |
2022-10-26 |
큐어백 아게 |
코로나바이러스 백신
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
IL295445A
(en)
|
2020-02-10 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Preparations and methods for silencing vegf-a expression
|
|
JP7735288B2
(ja)
|
2020-02-18 |
2025-09-08 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
アポリポタンパク質C3(APOC3)iRNA組成物およびその使用法
|
|
US12351834B2
(en)
|
2020-03-03 |
2025-07-08 |
Arcturus Therapeutics, Inc. |
Compositions and methods for the treatment of ornithine transcarbamylase deficiency
|
|
EP4114947A1
(en)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
|
BR112022017822A2
(pt)
|
2020-03-06 |
2022-11-08 |
Alnylam Pharmaceuticals Inc |
Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas
|
|
AU2021236068A1
(en)
|
2020-03-09 |
2022-10-06 |
Arcturus Therapeutics, Inc. |
Compositions and methods for inducing immune responses
|
|
JP2023520763A
(ja)
|
2020-03-24 |
2023-05-19 |
ジェネレーション バイオ カンパニー |
ゴーシェ治療薬を発現するための非ウイルス性dnaベクター及びその使用
|
|
US20230138409A1
(en)
|
2020-03-24 |
2023-05-04 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
|
TW202204615A
(zh)
|
2020-03-26 |
2022-02-01 |
美商阿尼拉製藥公司 |
冠狀病毒iRNA組成物及其使用方法
|
|
JP7746280B2
(ja)
|
2020-03-27 |
2025-09-30 |
ジェネレーション バイオ カンパニー |
新規脂質及びそれらのナノ粒子組成物
|
|
IL296781A
(en)
|
2020-03-30 |
2022-11-01 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
US11773391B2
(en)
|
2020-04-01 |
2023-10-03 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
|
|
US12534731B2
(en)
|
2020-04-01 |
2026-01-27 |
Alnylam Pharmaceuticals, Inc. |
Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof
|
|
KR20230008729A
(ko)
|
2020-04-06 |
2023-01-16 |
알닐람 파마슈티칼스 인코포레이티드 |
Myoc 발현을 사일런싱하기 위한 조성물 및 방법
|
|
JP2023521094A
(ja)
|
2020-04-07 |
2023-05-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Scn9a発現をサイレンシングするための組成物および方法
|
|
EP4133077A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
|
EP4133076A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
|
|
FI20215508A1
(en)
|
2020-04-09 |
2021-10-10 |
Niemelae Erik Johan |
Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
|
|
US12194157B2
(en)
|
2020-04-09 |
2025-01-14 |
Finncure Oy |
Carrier for targeted delivery to a host
|
|
IL297419B2
(en)
|
2020-04-22 |
2025-02-01 |
BioNTech SE |
Coronavirus vaccine
|
|
CN115997016A
(zh)
|
2020-04-27 |
2023-04-21 |
西克斯福德生物科学有限公司 |
包含具有模块化官能团的核酸纳米颗粒的组合物
|
|
IL297702A
(en)
|
2020-04-27 |
2022-12-01 |
Alnylam Pharmaceuticals Inc |
Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
|
|
JP2023523790A
(ja)
|
2020-04-30 |
2023-06-07 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
補体因子B(CFB)iRNA組成物およびその使用方法
|
|
CA3176844A1
(en)
|
2020-05-01 |
2021-11-04 |
Carlos G. PEREZ-GARCIA |
Nucleic acids and methods of treatment for cystic fibrosis
|
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
EP4150087A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
WO2021231675A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
EP4150090A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
IL298362A
(en)
|
2020-05-20 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Coronavirus antigen compositions and their uses
|
|
EP4153223A1
(en)
|
2020-05-20 |
2023-03-29 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
US20230183707A1
(en)
|
2020-05-21 |
2023-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
CA3170740A1
(en)
|
2020-05-29 |
2021-12-02 |
Curevac Ag |
Nucleic acid based combination vaccines
|
|
WO2021243301A2
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
KR20230029685A
(ko)
|
2020-05-29 |
2023-03-03 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
Trem 조성물 및 이에 관련된 방법
|
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
|
WO2021252649A2
(en)
|
2020-06-09 |
2021-12-16 |
Alnylam Pharmaceuticals, Inc. |
Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
|
|
EP4162050A1
(en)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
|
IL299094A
(en)
|
2020-06-15 |
2023-02-01 |
Res Inst Nationwide Childrens Hospital |
Administration of an adeno-associated virus vector for muscular dystrophies
|
|
WO2021257782A1
(en)
|
2020-06-18 |
2021-12-23 |
Alnylam Pharmaceuticals, Inc. |
XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
IL299571A
(en)
|
2020-07-08 |
2023-02-01 |
Janssen Sciences Ireland Unlimited Co |
Rna replicon vaccines against hbv
|
|
WO2022011156A1
(en)
*
|
2020-07-10 |
2022-01-13 |
Genevant Sciences Gmbh |
Lipid nanoparticles for delivering therapeutics to lungs
|
|
ES3054438T3
(en)
|
2020-07-16 |
2026-02-03 |
Acuitas Therapeutics Inc |
Cationic lipids for use in lipid nanoparticles
|
|
JP2023535632A
(ja)
|
2020-07-27 |
2023-08-18 |
アンジャリウム バイオサイエンシズ エージー |
Dna分子の組成物、その作製方法、及びその使用方法
|
|
WO2022023559A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
|
EP4196128A4
(en)
|
2020-08-14 |
2024-06-12 |
Arcturus Therapeutics, Inc. |
METHOD FOR FREEZE DILIZATION OF LIPID NANOPARTICLES
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
EP4157344A2
(en)
|
2020-08-31 |
2023-04-05 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
|
AU2021336976A1
(en)
|
2020-09-03 |
2023-03-23 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
IL301253A
(en)
|
2020-09-13 |
2023-05-01 |
Arcturus Therapeutics Inc |
As a mass of large RNA lipid nanoparticles
|
|
JP7518909B2
(ja)
|
2020-09-14 |
2024-07-18 |
富士フイルム株式会社 |
脂質組成物
|
|
JP2023549011A
(ja)
|
2020-09-15 |
2023-11-22 |
ヴァーヴ・セラピューティクス,インコーポレーテッド |
遺伝子編集のための脂質製剤
|
|
CA3192744A1
(en)
|
2020-09-23 |
2022-03-31 |
Oskar SMRZKA |
Compound for the sequestration of undesirable anti-peg antibodies in a patient
|
|
CZ310613B6
(cs)
|
2020-09-23 |
2026-01-28 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
|
EP4225917A1
(en)
|
2020-10-05 |
2023-08-16 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
|
EP4228658A4
(en)
|
2020-10-14 |
2025-02-19 |
George Mason Research Foundation, Inc. |
IONIZABLE LIPIDS AND METHODS FOR THE PRODUCTION AND USE THEREOF
|
|
CA3198823A1
(en)
|
2020-10-21 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
|
EP4232582A1
(en)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
|
WO2022099003A1
(en)
|
2020-11-06 |
2022-05-12 |
Sanofi |
Lipid nanoparticles for delivering mrna vaccines
|
|
KR20230107625A
(ko)
|
2020-11-13 |
2023-07-17 |
알닐람 파마슈티칼스 인코포레이티드 |
응고 인자 V(F5) iRNA 조성물 및 이의 사용 방법
|
|
WO2022115645A1
(en)
|
2020-11-25 |
2022-06-02 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
|
TW202237150A
(zh)
|
2020-12-01 |
2022-10-01 |
美商艾拉倫製藥股份有限公司 |
用於抑制hao1(羥基酸氧化酶1(乙醇酸氧化酶))基因表現的方法及組成物
|
|
KR20230128289A
(ko)
|
2020-12-03 |
2023-09-04 |
스크라이브 테라퓨틱스 인크. |
조작된 클래스 2 유형 v crispr 시스템
|
|
WO2022125490A1
(en)
|
2020-12-08 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
EP4262819A4
(en)
|
2020-12-21 |
2024-12-04 |
Beam Therapeutics Inc. |
NANOMATERIALS WITH ESTER-BOUND ACETALS
|
|
US11918643B2
(en)
|
2020-12-22 |
2024-03-05 |
CureVac SE |
RNA vaccine against SARS-CoV-2 variants
|
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
JP2024500879A
(ja)
*
|
2020-12-22 |
2024-01-10 |
コーネル ユニヴァーシティー |
双性イオン性脂質ナノ粒子組成物およびその使用方法
|
|
IL303886A
(en)
|
2020-12-23 |
2023-08-01 |
Flagship Pioneering Inc |
Compositions of modified trems and uses thereof
|
|
WO2022146654A1
(en)
|
2020-12-28 |
2022-07-07 |
Janssen Pharmaceuticals, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
|
JP7825997B2
(ja)
*
|
2020-12-28 |
2026-03-09 |
財團法人工業技術研究院 |
免疫刺激性リポプレックス、免疫刺激性リポプレックスを含む医薬組成物、およびその用途
|
|
EP4274896A1
(en)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component 9 (c9) irna compositions and methods of use thereof
|
|
CN116761888A
(zh)
|
2021-01-20 |
2023-09-15 |
比姆医疗股份有限公司 |
纳米材料
|
|
EP4281080A4
(en)
|
2021-01-20 |
2025-09-24 |
Beam Therapeutics Inc |
NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT
|
|
MX2023007788A
(es)
|
2021-01-24 |
2023-11-17 |
Michael David Forrest |
Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos.
|
|
US20240102065A1
(en)
|
2021-01-27 |
2024-03-28 |
CureVac SE |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
|
EP4291654A2
(en)
|
2021-02-12 |
2023-12-20 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
EP4298220A1
(en)
|
2021-02-25 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Prion protein (prnp) irna compositions and methods of use thereof
|
|
AU2022226098A1
(en)
|
2021-02-26 |
2023-08-24 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
IL305353A
(en)
|
2021-02-26 |
2023-10-01 |
Ethris Gmbh |
Formulations for aerosol formation and aerosols for the delivery of nucleic acid
|
|
JP2024508896A
(ja)
|
2021-03-04 |
2024-02-28 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
アンジオポエチン様3(ANGPTL3)iRNA組成物およびその使用方法
|
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
|
CA3212653A1
(en)
|
2021-03-26 |
2022-09-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
TW202305133A
(zh)
|
2021-03-26 |
2023-02-01 |
英商米納治療有限公司 |
Tmem173 sarna組合物及其使用方法
|
|
EP4314296A2
(en)
|
2021-03-29 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
|
EP4313109A1
(en)
|
2021-03-31 |
2024-02-07 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
CA3171429A1
(en)
|
2021-03-31 |
2022-09-30 |
Alexander SCHWENGER |
Syringes containing pharmaceutical compositions comprising rna
|
|
EP4314293A1
(en)
|
2021-04-01 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
|
DK4319803T3
(da)
|
2021-04-08 |
2025-12-15 |
Vaxthera Sas |
Coronavirusvaccine omfattende et mosaikprotein
|
|
JP2024517427A
(ja)
|
2021-04-20 |
2024-04-22 |
アンジャリウム バイオサイエンシズ エージー |
アミロ-α-1,6-グルコシダーゼ、4-α-グルカノトランスフェラーゼをコードするDNA分子の組成物、その作製の方法、及びその使用の方法
|
|
US20240165044A1
(en)
|
2021-04-22 |
2024-05-23 |
Inventage Lab Inc. |
Lipid nanoparticle preparation method and preparation apparatus therefor
|
|
EP4330392A1
(en)
|
2021-04-26 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
|
|
US20240216535A1
(en)
|
2021-04-27 |
2024-07-04 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
AU2022264509A1
(en)
|
2021-04-27 |
2023-12-14 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
WO2022232343A1
(en)
|
2021-04-29 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
|
EP4334446A1
(en)
|
2021-05-03 |
2024-03-13 |
CureVac SE |
Improved nucleic acid sequence for cell type specific expression
|
|
EP4341401A1
(en)
|
2021-05-18 |
2024-03-27 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
|
EP4341405A1
(en)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
WO2022244831A1
(en)
|
2021-05-21 |
2022-11-24 |
Okinawa Institute Of Science And Technology School Corporation |
Coronavirus vaccine suitable for elderly individuals
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
EP4347823A1
(en)
|
2021-06-02 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
EP4347822A2
(en)
|
2021-06-04 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
|
|
AR126070A1
(es)
|
2021-06-08 |
2023-09-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
|
|
EP4352215A1
(en)
|
2021-06-11 |
2024-04-17 |
LifeEDIT Therapeutics, Inc. |
Rna polymerase iii promoters and methods of use
|
|
CN117460542A
(zh)
|
2021-06-11 |
2024-01-26 |
纳米智能生物医学工程有限公司 |
包含用于将寡核苷酸递送至靶细胞内的肽-脂质缀合物的纳米颗粒以及包含其的药物组合物
|
|
AU2022291742A1
(en)
|
2021-06-14 |
2023-12-21 |
Generation Bio Co. |
Cationic lipids and compositions thereof
|
|
CA3222851A1
(en)
|
2021-06-22 |
2022-12-29 |
Roy VAN DER MEEL |
Nucleic acid containing nanoparticles
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
EP4363574A1
(en)
|
2021-06-29 |
2024-05-08 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
AU2022303164A1
(en)
|
2021-06-30 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
|
US20230044997A1
(en)
|
2021-07-15 |
2023-02-09 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
|
|
US20230042860A1
(en)
|
2021-07-15 |
2023-02-09 |
Turn Biotechnologies, Inc. |
Polycistronic expression vectors
|
|
WO2023288288A1
(en)
|
2021-07-15 |
2023-01-19 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
|
|
CZ310443B6
(cs)
|
2021-07-19 |
2025-06-25 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
MX2024000981A
(es)
|
2021-07-21 |
2024-02-12 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) de gen diana asociado con trastorno metabolico y sus metodos de uso.
|
|
AU2022316139A1
(en)
|
2021-07-23 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
|
EP4377457A1
(en)
|
2021-07-26 |
2024-06-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and uses thereof
|
|
US20250258180A1
(en)
|
2021-07-27 |
2025-08-14 |
Stand Therapeutics Co., Ltd. |
Peptide tag and nucleic acid encoding same
|
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
|
US20240342206A1
(en)
|
2021-07-30 |
2024-10-17 |
CureVac SE |
mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
|
|
CA3227852A1
(en)
|
2021-08-03 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
|
EP4381071A1
(en)
|
2021-08-04 |
2024-06-12 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing angiotensinogen (agt)
|
|
CN118076737A
(zh)
|
2021-08-13 |
2024-05-24 |
阿尔尼拉姆医药品有限公司 |
因子XII(F12)iRNA组合物及其使用方法
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
JP2024538859A
(ja)
|
2021-08-31 |
2024-10-24 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
細胞死誘導DFFA様エフェクターB(CIDEB)iRNA組成物およびその使用方法
|
|
US20240398940A1
(en)
|
2021-09-03 |
2024-12-05 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
US20240398933A1
(en)
|
2021-09-03 |
2024-12-05 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
CN118317944A
(zh)
|
2021-09-14 |
2024-07-09 |
雷纳嘉德医疗管理公司 |
非环状脂质及其使用方法
|
|
MX2024003262A
(es)
|
2021-09-17 |
2024-06-19 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y metodos para producir poliribonucleotidos circulares.
|
|
JP2024535850A
(ja)
|
2021-09-17 |
2024-10-02 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
補体成分(C3)をサイレンシングするためのiRNA組成物および方法
|
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
|
GB2625500B
(en)
|
2021-09-21 |
2026-04-01 |
Scribe Therapeutics Inc |
Engineered CasX repressor systems
|
|
TW202328449A
(zh)
|
2021-09-24 |
2023-07-16 |
美商艾拉倫製藥公司 |
微管相關蛋白TAU(MAPT)iRNA試劑組合物及其使用方法
|
|
CN118369427A
(zh)
|
2021-10-15 |
2024-07-19 |
阿尔尼拉姆医药品有限公司 |
肝外递送irna组合物及其使用方法
|
|
CA3235625A1
(en)
|
2021-10-18 |
2023-04-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
WO2023069603A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
CN118302525A
(zh)
|
2021-10-29 |
2024-07-05 |
阿尔尼拉姆医药品有限公司 |
补体因子B(CFB)iRNA组合物及其使用方法
|
|
EP4422698A1
(en)
|
2021-10-29 |
2024-09-04 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
EP4423272A2
(en)
|
2021-10-29 |
2024-09-04 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
TW202334080A
(zh)
|
2021-11-08 |
2023-09-01 |
美商歐納醫療公司 |
用於遞送環狀聚核苷酸之脂質奈米粒子組合物
|
|
KR102772764B1
(ko)
|
2021-11-10 |
2025-02-27 |
주식회사 에스엠엘바이오팜 |
트레할로즈 유도체 및 신규 구조 유지 화합물을 포함하는 핵산 의약품 전달용 지질나노입자의 약학 조성물
|
|
JP2024542188A
(ja)
|
2021-11-16 |
2024-11-13 |
セイル バイオメディシンズ インコーポレイテッド |
新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法
|
|
JP2024542260A
(ja)
|
2021-11-22 |
2024-11-13 |
セイル バイオメディシンズ インコーポレイテッド |
新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法
|
|
CN118401544A
(zh)
|
2021-11-24 |
2024-07-26 |
旗舰创业创新六公司 |
水痘-带状疱疹病毒免疫原组合物及其用途
|
|
EP4436984A1
(en)
|
2021-11-24 |
2024-10-02 |
Flagship Pioneering Innovations VI, LLC |
Coronavirus immunogen compositions and their uses
|
|
IL312965A
(en)
|
2021-11-24 |
2024-07-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and their uses
|
|
US12186387B2
(en)
|
2021-11-29 |
2025-01-07 |
BioNTech SE |
Coronavirus vaccine
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
KR20240118174A
(ko)
|
2021-12-17 |
2024-08-02 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
변성 조건 하에서의 원형 rna의 풍부화를 위한 방법
|
|
CA3241488A1
(en)
|
2021-12-20 |
2023-06-29 |
Beam Therapeutics Inc. |
Ionizable amine lipids and lipid nanoparticles
|
|
JP2025500824A
(ja)
|
2021-12-20 |
2025-01-15 |
ビーム セラピューティクス インク. |
四価脂質化合物を含むナノ材料
|
|
WO2023121970A1
(en)
|
2021-12-20 |
2023-06-29 |
Beam Therapeutics Inc. |
Ionizable amine and ester lipids and lipid nanoparticles
|
|
EP4452925A1
(en)
|
2021-12-20 |
2024-10-30 |
Beam Therapeutics Inc. |
Nanomaterial comprising diamines
|
|
EP4452942A1
(en)
|
2021-12-20 |
2024-10-30 |
Beam Therapeutics Inc. |
Nanomaterials comprising disulfides
|
|
EP4453201A1
(en)
|
2021-12-22 |
2024-10-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
EP4452928A1
(en)
|
2021-12-23 |
2024-10-30 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
US20230201817A1
(en)
|
2021-12-23 |
2023-06-29 |
Biontech Delivery Technologies Gmbh |
Modular drug production system
|
|
KR20240118881A
(ko)
|
2021-12-23 |
2024-08-05 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
항푸소제닉 폴리펩티드를 인코딩하는 원형 폴리리보뉴클레오티드
|
|
JP2025504404A
(ja)
|
2022-01-14 |
2025-02-12 |
アンジャリウム バイオサイエンシズ エージー |
Viii因子をコードするdna分子の組成物、それを作製する方法、及びその使用方法
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
|
CN118660708A
(zh)
*
|
2022-01-25 |
2024-09-17 |
公益财团法人川崎市产业振兴财团 |
用于经皮给药的含有rna的组合物和该组合物的给药方法
|
|
US20250345416A1
(en)
|
2022-01-27 |
2025-11-13 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
US20250099614A1
(en)
|
2022-01-28 |
2025-03-27 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
US20250327041A1
(en)
|
2022-02-24 |
2025-10-23 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
CN119072330A
(zh)
|
2022-03-14 |
2024-12-03 |
世代生物公司 |
异源初免加强疫苗组合物和使用方法
|
|
CN118891051A
(zh)
|
2022-03-15 |
2024-11-01 |
富士胶片株式会社 |
脂质组合物
|
|
WO2023178425A1
(en)
|
2022-03-23 |
2023-09-28 |
Nanovation Therapeutics Inc. |
High sterol-containing lipid nanoparticles
|
|
KR20240166554A
(ko)
|
2022-03-25 |
2024-11-26 |
세일 바이오메디슨스, 인크. |
신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법
|
|
WO2023184038A1
(en)
|
2022-04-01 |
2023-10-05 |
Nanovation Therapeutics Inc. |
Mrna delivery method and composition thereof
|
|
IL316038A
(en)
|
2022-04-04 |
2024-11-01 |
Univ California |
Preparations and methods for genetic complementation
|
|
AU2023251104A1
(en)
|
2022-04-07 |
2024-10-17 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
WO2023196634A2
(en)
|
2022-04-08 |
2023-10-12 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
|
US20250277059A1
(en)
|
2022-04-12 |
2025-09-04 |
Riken |
Antibody used to treat coronavirus infection
|
|
WO2023198828A1
(en)
|
2022-04-13 |
2023-10-19 |
Universitat Autònoma De Barcelona |
Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
|
|
AU2023260227A1
(en)
|
2022-04-27 |
2024-11-21 |
Shanghai Regenelead Therapies Co., Ltd |
Nucleic acid construct and use thereof
|
|
CA3257006A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
TREM COMPOSITIONS AND METHODS OF USE FOR TREATING PROLIFERATIVE DISORDERS
|
|
AU2023268051A1
(en)
|
2022-05-13 |
2025-01-02 |
BioNTech SE |
Rna compositions targeting hiv
|
|
TW202409283A
(zh)
|
2022-05-13 |
2024-03-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
雙股dna組合物及相關方法
|
|
TW202400784A
(zh)
|
2022-05-13 |
2024-01-01 |
大陸商上海瑞宏迪醫藥有限公司 |
包含utr的核酸構建體及其應用
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
WO2023230098A1
(en)
|
2022-05-23 |
2023-11-30 |
Logicbio Therapeutics, Inc. |
Gene therapy compositions and methods of use thereof
|
|
CA3256897A1
(en)
|
2022-05-25 |
2023-11-30 |
Akagera Medicines, Inc. |
Lipid nanoparticles for the administration of nucleic acids and their methods of use
|
|
US20250345407A1
(en)
|
2022-05-25 |
2025-11-13 |
CureVac SE |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
|
JP2025522297A
(ja)
|
2022-05-25 |
2025-07-15 |
ビオンテック エスエー |
サルポックス抗原の送達のためのrna組成物及び関連する方法
|
|
JP2025518221A
(ja)
|
2022-05-30 |
2025-06-12 |
ビオンテック・ソシエタス・エウロパエア |
核酸の送達のための複合体
|
|
WO2023235818A2
(en)
|
2022-06-02 |
2023-12-07 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
CA3258109A1
(en)
|
2022-06-03 |
2023-12-07 |
Bio-Trip B.V. |
LIPID NANOPARTICLES BASED ON MULTIPURPOSE MOLECULES FOR THE ADMINISTRATION OF NUCLEIC ACIDS
|
|
EP4536197A1
(en)
|
2022-06-07 |
2025-04-16 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
|
TW202413643A
(zh)
|
2022-06-07 |
2024-04-01 |
美商斯奎柏治療公司 |
用於靶向pcsk9的組合物及方法
|
|
GB2634837A
(en)
|
2022-06-07 |
2025-04-23 |
Scribe Therapeutics Inc |
Compositions and methods for the targeting of PCSK9
|
|
US20250179492A1
(en)
|
2022-06-22 |
2025-06-05 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
WO2024002985A1
(en)
|
2022-06-26 |
2024-01-04 |
BioNTech SE |
Coronavirus vaccine
|
|
JP2025525569A
(ja)
|
2022-07-18 |
2025-08-05 |
レナゲード セラピューティクス マネージメント インコーポレイテッド |
遺伝子編集成分、システム、及び使用方法
|
|
CA3260437A1
(en)
|
2022-07-20 |
2024-01-25 |
Beam Therapeutics Inc. |
NANOMATERIALS INCLUDING TRIOLS
|
|
EP4565604A2
(en)
|
2022-08-01 |
2025-06-11 |
Flagship Pioneering Innovations VII, LLC |
Immunomodulatory proteins and related methods
|
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
EP4569093A1
(en)
|
2022-08-12 |
2025-06-18 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
|
US20260055426A1
(en)
|
2022-08-19 |
2026-02-26 |
Generation Bio Co. |
CLEAVABLE CLOSED-ENDED DNA (ceDNA) AND METHODS OF USE THEREOF
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2024042236A1
(en)
|
2022-08-26 |
2024-02-29 |
Ethris Gmbh |
Stable lipid or lipidoid nanoparticle suspensions
|
|
EP4327829A1
(en)
|
2022-08-26 |
2024-02-28 |
Ethris GmbH |
Stabilization of lipid or lipidoid nanoparticle suspensions
|
|
US20260060926A1
(en)
|
2022-08-31 |
2026-03-05 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
EP4585591A1
(en)
|
2022-09-06 |
2025-07-16 |
Kyushu University, National University Corporation |
Lipid nanoparticles
|
|
EP4569113A1
(en)
|
2022-09-15 |
2025-06-18 |
Regeneron Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
|
EP4342460A1
(en)
|
2022-09-21 |
2024-03-27 |
NovoArc GmbH |
Lipid nanoparticle with nucleic acid cargo
|
|
IL319704A
(en)
|
2022-09-23 |
2025-05-01 |
Nchroma Bio Inc |
Compositions and methods for epigenetic regulation of HBV gene expression
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
JP2025533527A
(ja)
|
2022-09-23 |
2025-10-07 |
ビオンテック・ソシエタス・エウロパエア |
Plasmodium CSP抗原の送達のための組成物及び関連方法
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
WO2024064931A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of liver stage antigens and related methods
|
|
AU2023353931A1
(en)
|
2022-09-26 |
2025-03-20 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024074376A1
(en)
|
2022-09-27 |
2024-04-11 |
Resolution Therapeutics Limited |
Therapeutic macrophages
|
|
WO2024071319A1
(en)
|
2022-09-28 |
2024-04-04 |
Okinawa Institute Of Science And Technology School Corporation |
Composition comprising isolated or enriched phosphoenolpyruvate or a salt thereof
|
|
WO2024073588A1
(en)
*
|
2022-09-28 |
2024-04-04 |
Board Of Regents, The University Of Texas System |
Respiratory dry powder delivery
|
|
US20240174732A1
(en)
|
2022-10-05 |
2024-05-30 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
|
|
WO2024074634A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
EP4606372A1
(en)
|
2022-10-18 |
2025-08-27 |
Tipton Corp. |
Taylor reactor and capsule particle manufacturing method
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
EP4608442A1
(en)
|
2022-10-28 |
2025-09-03 |
GlaxoSmithKline Biologicals S.A. |
Nucleic acid based vaccine
|
|
EP4612296A1
(en)
|
2022-10-31 |
2025-09-10 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
WO2024102677A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
TW202434728A
(zh)
|
2022-11-08 |
2024-09-01 |
美商旗艦先鋒創新有限責任公司 |
用於產生環狀多核糖核苷酸的組成物和方法
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
AU2023406303A1
(en)
|
2022-12-01 |
2025-05-29 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
|
|
EP4626400A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
WO2024119074A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
|
EP4631528A1
(en)
|
2022-12-09 |
2025-10-15 |
Nibec Co., Ltd. |
Nanoparticle comprising peptide-based conjugate for delivering oligonucleotide into target cell and pharmaceutical composition comprising same
|
|
EP4631527A1
(en)
|
2022-12-09 |
2025-10-15 |
Seoul National University R&DB Foundation |
Nanoparticle comprising peptide-based conjugate for delivering mrna into b cell and t cell and uses thereof
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
WO2024125597A1
(en)
|
2022-12-14 |
2024-06-20 |
Providence Therapeutics Holdings Inc. |
Compositions and methods for infectious diseases
|
|
AU2023398825A1
(en)
|
2022-12-15 |
2025-06-26 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
AU2023410692A1
(en)
|
2022-12-20 |
2025-05-22 |
Stichting Amsterdam UMC |
Nucleic acid-lipid particles
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
EP4642797A1
(en)
|
2022-12-28 |
2025-11-05 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2024141784A2
(en)
|
2022-12-29 |
2024-07-04 |
Popvax Private Limited |
Broadly protective betacoronavirus vaccines and compositions
|
|
CN120435314A
(zh)
|
2022-12-29 |
2025-08-05 |
波普瓦克斯私人有限公司 |
多靶疫苗和治疗剂
|
|
WO2024147456A1
(ko)
|
2023-01-04 |
2024-07-11 |
(주)인벤티지랩 |
스파이럴 구조를 포함하는 지질 나노 입자 제조용 칩 및 이를 이용한 지질 나노 입자 제조 방법
|
|
WO2024151583A2
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
CN120936707A
(zh)
|
2023-01-19 |
2025-11-11 |
奥托斯实验室公司 |
再生因子在器官移植中的用途
|
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
|
WO2024167885A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
|
TW202449152A
(zh)
|
2023-02-09 |
2024-12-16 |
美商艾拉倫製藥股份有限公司 |
Reversir分子及其使用方法
|
|
CN121263425A
(zh)
|
2023-02-13 |
2026-01-02 |
旗舰创业创新第七有限责任公司 |
含可裂解接头的可电离脂质和用于治疗性组合物的脂质载体
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
IL322378A
(en)
|
2023-02-17 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
DNA compositions containing modified cytosine
|
|
EP4665405A1
(en)
|
2023-02-17 |
2025-12-24 |
Flagship Pioneering Innovations VII, LLC |
Dna compositions comprising modified uracil
|
|
WO2024184500A1
(en)
|
2023-03-08 |
2024-09-12 |
CureVac SE |
Novel lipid nanoparticle formulations for delivery of nucleic acids
|
|
AU2024236558A1
(en)
|
2023-03-15 |
2025-10-09 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
AU2024234874A1
(en)
|
2023-03-15 |
2025-10-09 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
EP4680750A1
(en)
|
2023-03-15 |
2026-01-21 |
Flagship Pioneering Innovations VI, LLC |
Compositions comprising polyribonucleotides and uses thereof
|
|
CN121013730A
(zh)
|
2023-03-15 |
2025-11-25 |
联合免疫股份有限公司 |
脂质颗粒
|
|
CN121358494A
(zh)
|
2023-03-15 |
2026-01-16 |
旗舰创业创新第六有限责任公司 |
免疫原性组合物及其用途
|
|
WO2024194767A1
(en)
|
2023-03-17 |
2024-09-26 |
BioNTech SE |
Automated drug production system
|
|
WO2024206565A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Repressor fusion protein systems
|
|
WO2024206676A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of lpa
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024206620A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Messenger rna encoding casx
|
|
PE20252746A1
(es)
|
2023-03-29 |
2025-12-05 |
Scribe Therapeutics Inc |
Composiciones y metodos para el direccionamiento a pcsk9
|
|
WO2024209418A1
(en)
|
2023-04-07 |
2024-10-10 |
BioNTech SE |
Heating and cooling jacket for fluid vessels
|
|
EP4695393A1
(en)
|
2023-04-12 |
2026-02-18 |
Flagship Pioneering Innovations VI, LLC |
Modified trems, compositions, and related methods thereof
|
|
EP4695391A1
(en)
|
2023-04-12 |
2026-02-18 |
Flagship Pioneering Innovations VI, LLC |
Trems for use in correction of missense mutations
|
|
WO2024213740A1
(en)
|
2023-04-14 |
2024-10-17 |
BioNTech SE |
Vaccine mixing method, syringe and system
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
AU2024260120A1
(en)
|
2023-04-27 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024228150A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024229309A2
(en)
|
2023-05-03 |
2024-11-07 |
Manifold Biotechnologies, Inc. |
Methodsand compositions for high-throughput protein delivery, screening, and detection
|
|
EP4705481A2
(en)
|
2023-05-05 |
2026-03-11 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
DE102023001946A1
(de)
|
2023-05-12 |
2024-11-14 |
Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts |
Nanopartikel für den Transport von Wirkstoffen mit anionischen Gruppen, Verfahren zu deren Herstellung und deren Verwendung
|
|
AU2024270764A1
(en)
|
2023-05-15 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024238700A1
(en)
|
2023-05-15 |
2024-11-21 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024240962A1
(en)
|
2023-05-25 |
2024-11-28 |
Ethris Gmbh |
Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof
|
|
AU2024279278A1
(en)
|
2023-05-31 |
2025-12-18 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
EP4732849A1
(en)
|
2023-06-22 |
2026-04-29 |
Kawasaki Institute of Industrial Promotion |
Method for improving stability of nucleic acid in blood and improving targeting efficiency of nucleic acid
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2025003406A1
(en)
|
2023-06-29 |
2025-01-02 |
BioNTech SE |
Modular multiplatform system for mrna drug production
|
|
WO2025007148A1
(en)
|
2023-06-30 |
2025-01-02 |
Orna Therapeutics, Inc. |
Polymer lipid nanoparticle compositions for delivering circular polynucleotides
|
|
WO2025008774A1
(en)
|
2023-07-05 |
2025-01-09 |
Takeda Pharmaceutical Company Limited |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
|
TW202515531A
(zh)
|
2023-07-07 |
2025-04-16 |
美商輝瑞股份有限公司 |
兩親性tlr7/8佐劑及其用途
|
|
WO2025015335A1
(en)
|
2023-07-13 |
2025-01-16 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
WO2025015338A1
(en)
|
2023-07-13 |
2025-01-16 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
TW202517784A
(zh)
|
2023-07-14 |
2025-05-01 |
大陸商云合智藥(蘇州)生物科技有限公司 |
用於抑制己酮糖激酶表達的RNAi劑及其應用
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
IL325865A
(en)
|
2023-07-21 |
2026-03-01 |
BioNTech SE |
Compositions for administering Plasmodium antigens and related methods
|
|
WO2025021083A1
(en)
*
|
2023-07-24 |
2025-01-30 |
National Institute Of Biological Sciences, Beijing |
Lipid nanoparticle compositions for localized treatment of skin diseases
|
|
WO2025024337A1
(en)
|
2023-07-24 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
KR20260044217A
(ko)
|
2023-07-25 |
2026-04-01 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
Cas 엔도뉴클레아제 및 관련 방법
|
|
WO2025022367A2
(en)
|
2023-07-27 |
2025-01-30 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
WO2025027089A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thiolipids and uses thereof
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
NL2035538B1
(en)
|
2023-08-03 |
2025-02-18 |
Univ Eindhoven Tech |
Lipid-like copolymers and method of producing these and the use thereof, pharmaceutical compositions comprising said copolymers, and the use of said compositions.
|
|
WO2025030097A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
CN121866336A
(zh)
|
2023-08-03 |
2026-04-14 |
百欧恩泰欧洲股份公司 |
靶向hiv的rna组合物
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
KR20260049597A
(ko)
|
2023-08-04 |
2026-04-14 |
알닐람 파마슈티칼스 인코포레이티드 |
Ctnnb1-관련 질환을 치료하기 위한 방법 및 조성물
|
|
US12162927B1
(en)
|
2023-08-09 |
2024-12-10 |
Wyvern Pharmaceuticals Inc. |
Compositions and methods for regulating production of an antibody like protein and ribonucleic acid
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025040139A1
(zh)
|
2023-08-23 |
2025-02-27 |
云合智药(苏州)生物科技有限公司 |
用于抑制二酰甘油-O-酰基转移酶2表达的RNAi剂及其应用
|
|
CN121729225A
(zh)
|
2023-08-25 |
2026-03-24 |
埃泽瑞斯公司 |
具有增强药物应用的特定表面活性剂性质的稳定脂质和类脂质纳米颗粒制剂
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
AU2024335327A1
(en)
|
2023-09-01 |
2026-03-26 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
IL326647A
(en)
|
2023-09-01 |
2026-04-01 |
Novoarc Gmbh |
Lipid nanoparticles with a nucleic acid charge and an ionizable lipid
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025051994A1
(en)
|
2023-09-07 |
2025-03-13 |
Coave Therapeutics |
Ionizable lipid nanoparticles
|
|
WO2025057088A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
WO2025064475A2
(en)
|
2023-09-18 |
2025-03-27 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025064660A2
(en)
|
2023-09-21 |
2025-03-27 |
Alnylam Pharmaceuticals, Inc. |
Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025072383A1
(en)
|
2023-09-25 |
2025-04-03 |
The Broad Institute, Inc. |
Viral open reading frames, uses thereof, and methods of detecting the same
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025072293A1
(en)
|
2023-09-27 |
2025-04-03 |
Scribe Therapeutics Inc. |
Optimized mrnas encoding casx proteins
|
|
AU2024352437A1
(en)
|
2023-09-27 |
2026-03-19 |
Resolution Therapeutics Limited |
Therapeutic macrophages
|
|
WO2025072699A1
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Aminoglycosides for delivery of agents to the kidney
|
|
WO2025072672A2
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Slc6a19-targeting modulatory nucleic acid agents
|
|
WO2025072713A1
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Polymyxins for delivery of agents to the kidney
|
|
WO2025076031A2
(en)
|
2023-10-03 |
2025-04-10 |
Alnylam Pharmaceuticals, Inc. |
Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
|
|
AU2024357861A1
(en)
|
2023-10-12 |
2026-04-23 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025083619A1
(en)
|
2023-10-18 |
2025-04-24 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and acive fragments and variants thereof and methods of use
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2025106670A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025106754A1
(en)
|
2023-11-15 |
2025-05-22 |
BioNTech SE |
Coronavirus vaccine
|
|
US12435338B2
(en)
|
2023-11-22 |
2025-10-07 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US20250161347A1
(en)
|
2023-11-22 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
US12195747B1
(en)
|
2023-11-22 |
2025-01-14 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12522830B2
(en)
|
2023-11-22 |
2026-01-13 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12559754B2
(en)
|
2023-11-22 |
2026-02-24 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
WO2025114520A1
(en)
|
2023-12-01 |
2025-06-05 |
Coave Therapeutics |
Ionizable lipid nanoparticles
|
|
WO2025128799A1
(en)
|
2023-12-12 |
2025-06-19 |
Korro Bio, Inc. |
Double-stranded rna-editing oligonucleotides and uses thereof
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025129158A1
(en)
|
2023-12-15 |
2025-06-19 |
The Broad Institute, Inc. |
Engineered arc delivery vesicles and uses thereof
|
|
US20250332281A2
(en)
|
2023-12-15 |
2025-10-30 |
Capstan Therapeutics, Inc. |
Humanized anti-cd8 antibodies and uses thereof
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025134062A2
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025144938A1
(en)
|
2023-12-26 |
2025-07-03 |
Emmune, Inc. |
Systems for nucleic acid transfer
|
|
WO2025140551A1
(en)
|
2023-12-29 |
2025-07-03 |
Neuro3 Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING NaV1.7 (SCN9A) -ASSOCIATED DISORDERS
|
|
WO2025149492A1
(en)
|
2024-01-08 |
2025-07-17 |
BioNTech SE |
Rna encoding an immune inhibitory il-1 family member
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
KR102716110B1
(ko)
|
2024-01-19 |
2024-10-15 |
(주) 멥스젠 |
다양한 크기를 갖는 지질나노입자 제조용 미세유체장치 및 이를 이용한 제조방법
|
|
TW202545974A
(zh)
|
2024-01-26 |
2025-12-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
免疫受體抑制蛋白及相關方法
|
|
WO2025166238A1
(en)
|
2024-01-31 |
2025-08-07 |
Orna Therapeutics, Inc. |
Fast-shedding polyethylene glycol lipids
|
|
WO2025166325A1
(en)
|
2024-02-02 |
2025-08-07 |
Editas Medicine, Inc. |
MODIFIED GUIDE RNAs
|
|
WO2025174908A1
(en)
|
2024-02-12 |
2025-08-21 |
Life Edit Therapeutics, Inc. |
Novel rna-guided nucleases and proteins for polymerase editing
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
US12281311B1
(en)
|
2024-02-20 |
2025-04-22 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12416020B2
(en)
|
2024-02-20 |
2025-09-16 |
Wyvern Pharmaceuticals Inc. |
Plasmid encoding a TLR3 and Fc fusion protein
|
|
US12540324B2
(en)
|
2024-02-20 |
2026-02-03 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12522831B2
(en)
|
2024-02-20 |
2026-01-13 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
WO2025184508A1
(en)
|
2024-03-01 |
2025-09-04 |
Acuitas Therapeutics, Inc. |
Materials and methods for encapsulating therapeutics in lipid nanoparticles
|
|
WO2025194138A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
St1cas9 compositions and methods for modulating a genome
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025199231A2
(en)
|
2024-03-20 |
2025-09-25 |
Vertex Pharmaceuticals Incorporated |
Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
WO2025202287A1
(en)
|
2024-03-26 |
2025-10-02 |
Resolution Therapeutics Limited |
Method of producing macrophages
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025219570A1
(en)
|
2024-04-17 |
2025-10-23 |
Johannes Kepler Universität Linz |
Composition for inhibiting protein translocation and methods using the same
|
|
KR20250157196A
(ko)
*
|
2024-04-26 |
2025-11-04 |
한국과학기술원 |
핵산 분자의 흡입 전달용 지질 나노복합체
|
|
WO2025228975A1
(en)
|
2024-04-29 |
2025-11-06 |
BioNTech SE |
Particles, compositions and methods
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|
|
US20250353881A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025240940A1
(en)
|
2024-05-17 |
2025-11-20 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of apolipoprotein c3
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025250808A1
(en)
|
2024-05-29 |
2025-12-04 |
The Brigham And Women’S Hospital, Inc. |
Anti-crispr delivery compositions and methods
|
|
WO2025259747A2
(en)
|
2024-06-12 |
2025-12-18 |
Alnylam Pharmaceuticals, Inc. |
Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
|
|
WO2025262460A1
(en)
|
2024-06-21 |
2025-12-26 |
BioNTech SE |
Lipid compositions for nucleic acid delivery
|
|
WO2026003754A1
(en)
|
2024-06-25 |
2026-01-02 |
Life Edit Therapeutics, Inc. |
Novel reverse transcriptases and uses thereof
|
|
US20260000702A1
(en)
|
2024-06-26 |
2026-01-01 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
WO2026003582A2
(en)
|
2024-06-27 |
2026-01-02 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2026015882A1
(en)
|
2024-07-12 |
2026-01-15 |
BioNTech SE |
Hsv antigen fragments and related methods
|
|
WO2026018213A1
(en)
|
2024-07-18 |
2026-01-22 |
Vaxthera Sas |
A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
|
|
WO2026020171A2
(en)
|
2024-07-19 |
2026-01-22 |
Aera Therapeutics, Inc. |
Chimeric antigen receptor constructs
|
|
US20260023050A1
(en)
|
2024-07-22 |
2026-01-22 |
Waters Technologies Corporation |
Methods for analyzing lipid nanoparticles and uses thereof
|
|
WO2026024954A2
(en)
|
2024-07-24 |
2026-01-29 |
Altos Labs, Inc. |
Use of regeneration factors in organ transplantation
|
|
WO2026027887A2
(en)
|
2024-08-02 |
2026-02-05 |
Mina Therapeutics Limited |
Hbg1/2-sarna compositions and methods of use
|
|
WO2026047603A1
(en)
|
2024-08-28 |
2026-03-05 |
BioNTech SE |
Sars-cov-2 immunogenic compositions
|
|
US12570983B2
(en)
|
2024-08-30 |
2026-03-10 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
WO2026055461A1
(en)
|
2024-09-05 |
2026-03-12 |
Aperture Therapeutics, Inc. |
Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof
|
|
WO2026055547A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions and related methods
|
|
WO2026055543A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Modified dna compositions and related methods
|
|
WO2026057626A1
(en)
|
2024-09-11 |
2026-03-19 |
BioNTech SE |
Peptidoglycan hydrolases having multiple enzymatically active domains
|
|
WO2026057625A1
(en)
|
2024-09-11 |
2026-03-19 |
BioNTech SE |
Peptidoglycan hydrolases having a chap domain with engineered active site
|
|
WO2026064313A1
(en)
|
2024-09-17 |
2026-03-26 |
Flagship Pioneering Innovations Vii, Llc |
Rna compositions and related methods
|
|
US12480129B1
(en)
|
2024-09-17 |
2025-11-25 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12509688B1
(en)
|
2024-09-17 |
2025-12-30 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
WO2026064512A1
(en)
|
2024-09-18 |
2026-03-26 |
Generation Bio Co. |
Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
US12480123B1
(en)
|
2024-09-20 |
2025-11-25 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12545917B1
(en)
|
2024-09-20 |
2026-02-10 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12486506B1
(en)
|
2024-09-20 |
2025-12-02 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12480121B1
(en)
|
2024-09-20 |
2025-11-25 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12503702B1
(en)
|
2024-09-25 |
2025-12-23 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
WO2026068864A1
(en)
|
2024-09-30 |
2026-04-02 |
BioNTech SE |
Engineered ch1 and cl domains for the prevention of chain mispairing
|
|
US12416021B1
(en)
|
2024-10-11 |
2025-09-16 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of proteins
|
|
WO2026085300A1
(en)
|
2024-10-16 |
2026-04-23 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods
|
|
WO2026082899A2
(en)
|
2024-10-16 |
2026-04-23 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
WO2026085495A1
(en)
|
2024-10-18 |
2026-04-23 |
Generation Bio Co. |
Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor
|
|
US12428654B1
(en)
|
2024-10-29 |
2025-09-30 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of proteins
|
|
US12416022B1
(en)
|
2024-10-29 |
2025-09-16 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of proteins
|
|
US12529059B1
(en)
|
2024-12-12 |
2026-01-20 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12509694B1
(en)
|
2024-12-12 |
2025-12-30 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12553046B1
(en)
|
2025-02-11 |
2026-02-17 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12565652B1
(en)
|
2025-03-27 |
2026-03-03 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12497618B1
(en)
|
2025-09-09 |
2025-12-16 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
CN121466311A
(zh)
*
|
2026-01-09 |
2026-02-06 |
羿美诚健(上海)生物医药有限公司 |
一种脂质组合物及其在核酸递送中的应用
|